Gilead's 4-drug combo shows early promise against hepatitis C

03/8/2011 | Bloomberg

A four-drug combination from Gilead Sciences showed promise during an early-stage trial in eliminating hepatitis C virus, RBC Capital Markets analysts said. The result supports an ongoing Phase II trial of the drug, which consists of Gilead's compounds GS-9256 and GS-9190 plus standard treatments ribavirin and pegylated interferon.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA